首页> 外文期刊>Nuclear Medicine and Biology >Tetradentate bis-phosphine ligands (P(2)N(2) and P(2)S(2)) and their Rh(III), Ni(II) and (105)Rh complexes: X-ray crystal structures of trans-(RhCl(2)(L2))PF(6), (Ni(L2))(PF(6))(2) and mu-O(2)SO(2)-(Ni(L5))(2)(PF(6))(2).
【24h】

Tetradentate bis-phosphine ligands (P(2)N(2) and P(2)S(2)) and their Rh(III), Ni(II) and (105)Rh complexes: X-ray crystal structures of trans-(RhCl(2)(L2))PF(6), (Ni(L2))(PF(6))(2) and mu-O(2)SO(2)-(Ni(L5))(2)(PF(6))(2).

机译:四齿双膦配体(P(2)N(2)和P(2)S(2))及其Rh(III),Ni(II)和(105)Rh络合物:反式X射线的X射线晶体结构(RhCl(2)(L2))PF(6),(Ni(L2))(PF(6))(2)和mu-O(2)SO(2)-(Ni(L5))(2) (PF(6))(2)。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

INTRODUCTION: Tetradentate acyclic and macrocyclic diphosphine ligands (P(2)N(2) and P(2)S(2)) have been synthesized and characterized as potential chelates for Rh(III). METHODS: The coordination complexes [RhCl(2)(L1)]Cl, trans-[RhCl(2)(L2)]PF(6), [Ni(L2)](PF(6))(2), [Ni(L3)](PF(6))(2), [RhCl(2)(L4)]PF(6) and [RhCl(2)(L5)]PF(6) have been synthesized and characterized. In addition, radiochemistry studies of the (105)Rh complexes with the ligands N,N'-bis[2-(diphenylphosphino)phenyl]-1,3-diaminopropane (L1), 4,8-diphenyl-1,11-diaza-4,8-diphosphaundecane (L2), 5,9-diphenyl-5,9-diphospha-2,12-dithiatridecane (L3) and 1,4,8,11-tetraphenyl-4,8-diphospha-1,11-dithiaundecane (L4) are reported, including normal mouse biodistributions of (105)Rh-L2. RESULTS: trans-[RhCl(2)(L2)]PF(6) crystallized in the monoclinic space group P2(1)/c with a = 9.9353(5) A, b = 9.0929(5) A, c = 28.689(1) A, beta = 93.1400(10) deg, Z = 4, R = 0.037 and R(w) = 0.053. [Ni(L2)](PF(6))(2) crystallized in the monoclinic space group P2(1)/c with a = 11.9665(6) A, b = 14.8903(7) A, c = 31.148(1) A, beta = 91.587(1) deg, Z = 8, R = 0.056 and R(w) = 0.083. mu-O(2)SO(2)-[Ni(L5)](2)(PF(6))(2), an unusual sulfate-bridged Ni(II) dimer, crystallized in the triclinic space group P1 bar with a = 15.179(2) A, b = 15.514(2) A, c = 16.128(2) A, alpha = 105.280(7) deg, beta = 113.074(6) deg, gamma = 101.657(8) deg, Z = 2, R = 0.050 and R(w) = 0.072. CONCLUSIONS: Phosphine-containing ligands allowed for lower temperatures and lower ethanol concentrations in the formulations for (105)Rh(L) complexation, but at the expense of higher ligand concentrations.
机译:简介:四齿无环和大环二膦配体(P(2)N(2)和P(2)S(2))已合成并表征为Rh(III)的潜在螯合物。方法:配位化合物[RhCl(2)(L1)] Cl,反式-[RhCl(2)(L2)] PF(6),[Ni(L2)](PF(6))(2),[Ni (L3)](PF(6))(2),[RhCl(2)(L4)] PF(6)和[RhCl(2)(L5)] PF(6)已合成并表征。此外,(105)Rh配合物与配体N,N'-双[2-(二苯基膦基)苯基] -1,3-二氨基丙烷(L1),4,8-二苯基-1,11-二氮杂的放射化学研究-4,8-​​二磷十一烷(L2),5,9-二苯基-5,9-二磷-2,12-二噻十三烷(L3)和1,4,8,11-四苯基-4,8-​​二磷-1,11 -dithiaundecane(L4),包括(105)Rh-L2的正常小鼠生物分布。结果:反式-[RhCl(2)(L2)] PF(6)在单斜空间群P2(1)/ c中结晶,a = 9.9353(5)A,b = 9.0929(5)A,c = 28.689( 1)A,β= 93.1400(10)度,Z = 4,R = 0.037和R(w)= 0.053。 [Ni(L2)] [PF(6))(2)在单斜空间群P2(1)/ c中结晶,a = 11.9665(6)A,b = 14.8903(7)A,c = 31.148(1) A,β= 91.587(1)度,Z = 8,R = 0.056和R(w)= 0.083。 mu-O(2)SO(2)-[Ni(L5)](2)(PF(6))(2),一种不寻常的硫酸盐桥连的Ni(II)二聚体,在三斜空间群P1 bar中具有a = 15.179(2)A,b = 15.514(2)A,c = 16.128(2)A,alpha = 105.280(7)度,beta = 113.074(6)度,γ= 101.657(8)度,Z =在图2中,R = 0.050,R(w)= 0.072。结论:含膦的配体可降低(105)Rh(L)络合制剂的温度和乙醇浓度,但要以较高的配体浓度为代价。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号